- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Codexis Inc (CDXS)
The Codexis share price today is 1.460, view NASDAQ CDXS stock exchange data. Track the latest Codexis share price with real-time updates on CDXS stock performance including market cap, day range, 52-week range and dividend yield. Access CDXS charts, earnings dates and analyst estimates to support your investment decisions.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.430
1.483
52 wk Range
0.958
2.980
CDXS is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.4301.483
52 wk Range
0.9582.980
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
CDXS Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
6.333
Upside
+333.79%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Stock price movements are quite volatile
Codexis receives Investment Bank Analyst Rating Update- Investing.com
Pro
- Codexis receives Investment Bank Analyst Rating Update
- Investing.com
Pro 
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Sell
Moving Averages
Sell
Analyst Ratings
5 Buy
2 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 6.333
(+333.79% Upside)
Codexis Inc SWOT Analysis
Enzymatic Revolution | Codexis pivots to RNAi therapeutics manufacturing, leveraging its ECO Synthesis platform to address critical challenges in drug production scalability and efficiency |
Market Opportunity | Explore the billion-dollar potential in the growing RNAi therapeutics market, where Codexis aims to revolutionize manufacturing processes with its innovative approach |
Financial Fortitude | Delve into Codexis's robust financial position, with $90.3 million in cash reserves providing runway until 2027, despite current negative EBITDA of -$45.78 million |
Analyst Outlook | Cantor Fitzgerald maintains a consistent $11.00 price target throughout 2024, reflecting cautious optimism about Codexis's potential in the RNAi manufacturing arena |
Codexis Inc Earnings Call Summary for Q2/2026
- Codexis posted Q2 2026 revenue of $14.92M, beating estimates by 7.96%, with a 13-cent loss per share versus 14-cent forecast.
- Product gross margin improved to 73% as R&D and SG&A expenses fell 15.2% and 11.4% respectively; cash runway extended through 2028.
- Company maintained full-year 2026 revenue guidance of $72M-$76M with gross margin in high 60s, expecting back-half weighted results.
- ECO Synthesis platform showed progress with stereochemistry control and starterless RNA synthesis; GMP facility planned to scale production.
- One of three CDMO partners entered long-term commercial contract talks; management targets 500-gram scale by year-end, then kilogram scale.
Last Updated: 12-08-2026, 03:04 am
Read Full TranscriptEarnings
Latest Release
11-08-2026
EPS / Forecast
-0.13 / -0.14
Revenue / Forecast
14.92M / 13.82M
Compare CDXS to Peers and Sector
Metrics to compare | CDXS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCDXSPeersSector | |
|---|---|---|---|---|
P/E Ratio | −5.2x | −1.6x | −0.4x | |
PEG Ratio | −0.09 | −0.01 | 0.00 | |
Price/Book | 4.9x | 4.9x | 2.6x | |
Price / LTM Sales | 2.1x | 9.2x | 3.0x | |
Upside (Analyst Target) | 348.3% | 49.8% | 48.7% | |
Fair Value Upside | Unlock | −2.4% | 7.0% | Unlock |
Codexis, Inc. provides technology solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, enhance, and commercialize novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a license agreement with Aldevron LLC and Pfizer Inc. The company was incorporated in 2002 and is headquartered in Redwood City, California.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Codexis (CDXS) Share Price Today?
The Codexis share price today is 1.460.
What is the current Codexis (CDXS) share price and day range?
As of 05-09-2026, the Codexis share price is 1.460, with a previous close of 1.420. The share price has ranged from 1.430 to 1.483 today, while the 52-week range spans from 0.958 to 2.980.
What Is the Codexis Market Cap?
As of today, Codexis market cap is 155.500M.
What Is the Codexis (CDXS) Share Price Target?
The average 12-month share price target for Codexis is 6.333, with a high estimate of 11 and a low estimate of 2. 5 analysts recommend buying, while 0 suggest selling, with an overall rating of Buy and +333.79% Upside potential.
What Is Codexis's Earnings Per Share (TTM)?
The Codexis EPS (TTM) is -0.339.
When Is the Next Codexis Earnings Date?
Codexis will release its next earnings report on 29-10-2026.
From a Technical Analysis Perspective, Is CDXS a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
What Stock Exchange Does Codexis Trade On?
Codexis is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Codexis?
The stock symbol for Codexis is "CDXS."
How Many Times Has Codexis Stock Split?
Codexis has split 0 times.
How Many Employees Does Codexis Have?
Codexis has 146 employees.
What Is the CDXS Premarket Price?
CDXS's last pre-market stock price is 1.500. The pre-market share volume is 2,900.000, and the stock has changed by 0.080, or 5.630%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.